Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: Classification into five treatment groups

Kei Ito; Naoki Nakamura; Takuya Shimizuguchi; Hiroaki Ogawa; Katsuyuki Karasawa

doi:10.1016/j.rpor.2019.12.018

Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: Classification into five treatment groups

Rep Pract Oncol Radiother. 2020 Jan-Feb;25(1):150-153. doi: 10.1016/j.rpor.2019.12.018. Epub 2019 Dec 18.

Authors

Kei Ito¹, Naoki Nakamura², Takuya Shimizuguchi¹, Hiroaki Ogawa¹, Katsuyuki Karasawa¹

Affiliations

¹ Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
² Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan.

Abstract

Treatment of bone metastasis using stereotactic body radiotherapy (SBRT) is being widely used in clinical practice. The reported clinical advantages of SBRT include high pain and local control rates, high response rates against bone metastasis from radio-resistant tumors, and safe re-irradiations. Although most reports in the literature use local control as the primary treatment endpoint, this endpoint is not appropriate because local control does not relate directly to patient benefit. Herein, we proposed five pathophysiology-based patient groups, as well as appropriate endpoints for each group.

Keywords: Endpoints; SBRT; Spine and non-spine bone metastasis; Treatment purpose.

Publication types

Review